TY - JOUR
T1 - Estrogen receptor beta-mediated modulation of lung cancer cell proliferation by 27-hydroxycholesterol
AU - Hiramitsu, Shiro
AU - Ishikawa, Tomonori
AU - Lee, Wan Ru
AU - Khan, Tamor
AU - Crumbley, Christine
AU - Khwaja, Nimra
AU - Zamanian, Faezeh
AU - Asghari, Arvand
AU - Sen, Mehmet
AU - Zhang, Yang
AU - Hawse, John R.
AU - Minna, John D.
AU - Umetani, Michihisa
N1 - Funding Information:
We thank Drs. Philip Shaul (UT Southwestern), Jan-Ake Gustafsson (University of Houston) and their lab members, Anders Strom, Surendra Chaurasiya, Shivangi Srivastava (University of Houston), and Kendra Carmon (UT-Health) for their technical help, thoughtful discussions, and suggestions. This work was supported by National Institutes of Health grants P03DK079328 (MU) and UH CNRCS Startup Fund (MU).
Publisher Copyright:
© 2018 Hiramitsu, Ishikawa, Lee, Khan, Crumbley, Khwaja, Zamanian, Asghari, Sen, Zhang, Hawse, Minna and Umetani.
PY - 2018/8/23
Y1 - 2018/8/23
N2 - 27-hydroxycholesterol (27HC) is an abundant cholesterol metabolite in human circulation and promotes breast cancer cell proliferation. Although lung is one of the organs that contain high levels of 27HC, the role of 27HC in lung is unknown. In this study, we found that 27HC promotes lung cancer cell proliferation in an estrogen receptor β (ERβ)-dependent manner. The expression of 27HC-generating enzyme CYP27A1 is higher in lung cancer cells than in normal lung cells. Treatment with 27HC increased cell proliferation in ERβ-positive lung cancer cells, but not in ERα-positive or ER-negative cells. The effect on cell proliferation is specific to 27HC and another oxysterol, 25-hydroxycholesterol that has a similar oxysterol structure with 27HC. Moreover, among ligands for nuclear receptors tested, only estrogen had the proliferative effect, and the effect by 27HC and estrogen was inhibited by ERβ-specific, but not ERα-specific, inhibitors. In addition, the effect by 27HC was not affected by membrane-bound estrogen receptor GPR30. Interestingly, despite the high expression of CYP27A1, endogenously produced 27HC was not the major contributor of the 27HC-induced cell proliferation. Using kinase inhibitors, we found that the effect by 27HC was mediated by the PI3K-Akt signaling pathway. These results suggest that 27HC promotes lung cancer cell proliferation via ERβ and PI3K-Akt signaling. Thus, lowering 27HC levels may lead to a novel approach for the treatment of lung cancer.
AB - 27-hydroxycholesterol (27HC) is an abundant cholesterol metabolite in human circulation and promotes breast cancer cell proliferation. Although lung is one of the organs that contain high levels of 27HC, the role of 27HC in lung is unknown. In this study, we found that 27HC promotes lung cancer cell proliferation in an estrogen receptor β (ERβ)-dependent manner. The expression of 27HC-generating enzyme CYP27A1 is higher in lung cancer cells than in normal lung cells. Treatment with 27HC increased cell proliferation in ERβ-positive lung cancer cells, but not in ERα-positive or ER-negative cells. The effect on cell proliferation is specific to 27HC and another oxysterol, 25-hydroxycholesterol that has a similar oxysterol structure with 27HC. Moreover, among ligands for nuclear receptors tested, only estrogen had the proliferative effect, and the effect by 27HC and estrogen was inhibited by ERβ-specific, but not ERα-specific, inhibitors. In addition, the effect by 27HC was not affected by membrane-bound estrogen receptor GPR30. Interestingly, despite the high expression of CYP27A1, endogenously produced 27HC was not the major contributor of the 27HC-induced cell proliferation. Using kinase inhibitors, we found that the effect by 27HC was mediated by the PI3K-Akt signaling pathway. These results suggest that 27HC promotes lung cancer cell proliferation via ERβ and PI3K-Akt signaling. Thus, lowering 27HC levels may lead to a novel approach for the treatment of lung cancer.
KW - 27-hydroxycholesterol
KW - Cholesterol metabolites
KW - ERβ
KW - Estrogen receptor
KW - Lung cancer
UR - http://www.scopus.com/inward/record.url?scp=85052195727&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052195727&partnerID=8YFLogxK
U2 - 10.3389/fendo.2018.00470
DO - 10.3389/fendo.2018.00470
M3 - Article
AN - SCOPUS:85052195727
SN - 1664-2392
VL - 9
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
IS - AUG
M1 - 470
ER -